Trending...
- Yet another EU country´s Data Protection Authority makes it official! Google Analytics is out!
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Yatsen Holding Limited with Losses of $100,000 to Contact the Firm
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Barclays PLC with Losses of $100,000 to Contact the Firm
CARLSBAD, Calif. - Californer -- Universal Sequencing Technology Corporation (UST), announces today, August 2nd, 2022, that it has released "TELL-Seq Haplotype Phasing" App on Illumina Basespace™ Sequence Hub to further streamline and enable access to the TELL-Seq haplotype phasing workflow solution. This can effectively be used in broad research areas including genetic disease research, HLA haplotyping, complex variant linkage, and trait analysis.
UST's TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb up to and exceeding 200kb). Sequencing ready libraries can be prepared quickly in ~3 hours, with a simple workflow, and cost effectively with only basic lab equipment.
Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, stated that "TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and Illumina, based on the co-development and co-marketing agreement signed early 2021, is speeding up the adoption of UST's super long range TELL-Seq NGS library products among Illumina users, in the US and all over the world."
Dr. Dalia Daujotyte, Director of NGS Partnerships and Applications at Illumina, stated that "TELL-Seq linked read technology provides valuable solutions that enrich the Illumina ecosystem and we have been pleased to partner with UST."
More on The Californer
To demonstrate the capabilities of the TELL-Seq phasing workflow and new BSSH app, UST and Illumina have co-developed and released the application note "Ultra-long range phasing with linked-read sequencing technology." By combining highly accurate Illumina sequencing and UST TELL-Seq library technology the app note demonstrates excellent haplotype phasing performance and enables users to generate phasing block greater than >10Mb and libraries with N50 phasing blocks >1Mb with human whole genome when utilizing high molecular weight input DNA.
It has been demonstrated that TELL-Seq can phase the entire 4Mb major histocompatibility complex (MHC) region into two complete parental haplotypes (Chen et al, Genome Res. 2020 Jun;30(6):898-909. doi: 10.1101/gr.260380,119). MHC region contains many highly polymorphic HLA genes which play a critical role in organ transplantation and are associated with many diseases.
According to Dr. Zhoutao (Tom) Chen, Chief Scientific Officer of UST, "With super long-range TELL-Seq library kit and an Illumina sequencer, one can now perform de novo sequencing (microbial genomes, metagenomics, animals/plants/insects, etc.), whole genome phasing, and structural variation detection, as well as generate phased whole exome and target sequencing. Unique to this technology, it requires very low input DNA, 3-5ng for large genomes (>2Gb) and 0.1-0.5ng for small genomes (<10Mb) and targeted gene panels."
More on The Californer
A recent Nature Medicine article (Kumar et al. Nat Med 28, 513–516, 2022. https://doi.org/10.1038/s41591-022-01735-0 ) demonstrated superior TELL-Seq phasing results to detect phased rare variants with high accuracy for whole-genome risk prediction of common diseases in human preimplantation embryos. In addition to genome-scale phasing application, TELL-Seq has been used successfully in targeted phasing applications, such as, phased whole exome sequencing, phasing enriched full length gene targets, e.g., 200kb BRCA1 and BRCA2 genes, and phasing 2kb to 15kb long-range PCR amplicons.
Dr. Ming Lei, Co-Founder and CEO of UST also added that " we are continuing to advance our technology and expand our product pipeline into multiple NGS application areas that require super long read. We will continue to partner with Illumina to support further expansion of Illumina sequencing platforms' applications, based on our co-development, co-marketing, and commercial agreement."
ABOUT UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION
Universal Sequencing Technology Corporation (UST), a Boston and San Diego based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to the development of the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single cell sequencing and groundbreaking 3rd generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.
UST's TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb up to and exceeding 200kb). Sequencing ready libraries can be prepared quickly in ~3 hours, with a simple workflow, and cost effectively with only basic lab equipment.
Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, stated that "TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and Illumina, based on the co-development and co-marketing agreement signed early 2021, is speeding up the adoption of UST's super long range TELL-Seq NGS library products among Illumina users, in the US and all over the world."
Dr. Dalia Daujotyte, Director of NGS Partnerships and Applications at Illumina, stated that "TELL-Seq linked read technology provides valuable solutions that enrich the Illumina ecosystem and we have been pleased to partner with UST."
More on The Californer
- Sydney Brachytherapy Group is the first private non-melanoma skin cancer clinic in Sydney to offer OncoBeta's Rhenium-SCT
- PermaTherm Announces Panels Delivered Quickly Program
- General Inception Creates First-Ever "Igniter" for New Company Formation
- ASI Hosts 24th Annual iNNOVATIONS Conference and Announces Award Winners
- NuVasive Announces Agenda for Investor Day 2022
To demonstrate the capabilities of the TELL-Seq phasing workflow and new BSSH app, UST and Illumina have co-developed and released the application note "Ultra-long range phasing with linked-read sequencing technology." By combining highly accurate Illumina sequencing and UST TELL-Seq library technology the app note demonstrates excellent haplotype phasing performance and enables users to generate phasing block greater than >10Mb and libraries with N50 phasing blocks >1Mb with human whole genome when utilizing high molecular weight input DNA.
It has been demonstrated that TELL-Seq can phase the entire 4Mb major histocompatibility complex (MHC) region into two complete parental haplotypes (Chen et al, Genome Res. 2020 Jun;30(6):898-909. doi: 10.1101/gr.260380,119). MHC region contains many highly polymorphic HLA genes which play a critical role in organ transplantation and are associated with many diseases.
According to Dr. Zhoutao (Tom) Chen, Chief Scientific Officer of UST, "With super long-range TELL-Seq library kit and an Illumina sequencer, one can now perform de novo sequencing (microbial genomes, metagenomics, animals/plants/insects, etc.), whole genome phasing, and structural variation detection, as well as generate phased whole exome and target sequencing. Unique to this technology, it requires very low input DNA, 3-5ng for large genomes (>2Gb) and 0.1-0.5ng for small genomes (<10Mb) and targeted gene panels."
More on The Californer
- Lionrock Adds Ketamine Assisted Psychotherapy Program to State-of-the-Art Treatment Offerings for Substance Use Disorder
- Mystery Thriller Film "Mile 19" Announces VOD Release Date and Three City Promo Tour
- Announcing Lizzy Stevens Becoming An Award Winning Author
- California: Governor Newsom Issues Legislative Update 9.28.22
- Capitol Music Group signs Travis Japan, Japanese boy band from Johnny & Associates USA - English USA - English
A recent Nature Medicine article (Kumar et al. Nat Med 28, 513–516, 2022. https://doi.org/10.1038/s41591-022-01735-0 ) demonstrated superior TELL-Seq phasing results to detect phased rare variants with high accuracy for whole-genome risk prediction of common diseases in human preimplantation embryos. In addition to genome-scale phasing application, TELL-Seq has been used successfully in targeted phasing applications, such as, phased whole exome sequencing, phasing enriched full length gene targets, e.g., 200kb BRCA1 and BRCA2 genes, and phasing 2kb to 15kb long-range PCR amplicons.
Dr. Ming Lei, Co-Founder and CEO of UST also added that " we are continuing to advance our technology and expand our product pipeline into multiple NGS application areas that require super long read. We will continue to partner with Illumina to support further expansion of Illumina sequencing platforms' applications, based on our co-development, co-marketing, and commercial agreement."
ABOUT UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION
Universal Sequencing Technology Corporation (UST), a Boston and San Diego based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to the development of the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single cell sequencing and groundbreaking 3rd generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.
Source: Universal Sequencing Technology Corporation
Filed Under: Biotech
0 Comments
Latest on The Californer
- California: On the Record with Governor Gavin Newsom: Saving Water & Building a More Resilient Future
- ATEN Technology Renovates the Desktop for the Hybrid Work Challenge with New KVM Switch
- Experienced Intellectual Property Attorney Christopher Franich Joins Snell & Wilmer's SD Office
- Triunfo Water & Sanitation District Board Approves Reducing Sprinkler Irrigation Time
- Edge AI Innovator Femtosense Raises $8 Million Series A Funding
- CHIRLA, IMMIGRANT RIGHTS GROUPS MOBILIZE IN SUPPORT OF BILL TO EXPAND A PATHWAY FOR RESIDENCY FOR MILLIONS OF LONG-TERM RESIDENTS.
- BEAR Technologies Successfully Completes 2022 SOC 2 Type II Audit
- Exterro Launches FTK® Suite 7.6, Introducing Mobile Parsing, Automation Capabilities, And Industry-First Remote Endpoint Triage
- Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody
- Honda Advances Support of Hispanic Scholarship Fund with $1 Million Donation
- Re-Introducing Gigahurtz, DJ and Producer
- Pureboost, Amazon's #1 Selling Clean Energy Drink, Raises Over $2M+ Within Hours of Launching Community Round to the Public on Wefunder's Community Investment Platform
- Creating a Telegram sticker pack for brand advertising
- Leopard Imaging to Showcase at VISION in Stuttgart with 2D and 3D Depth Cameras Empowered by onsemi
- Shana Tovah! Happy Rosh Hashanah!
- Tigo Energy Surpasses One-Terawatt Hour of Monitored Solar PV Energy in Europe
- California: Governor Newsom Issues Legislative Update 9.27.22
- 20th Annual Oakland International Film Festival Launches Yearlong Celebration
- South Asian Streaming Service Cpics Expands Executive Board, Announces Head of Programming
- Lightbits and Intel to Demonstrate Application Acceleration and Improved Resource Utilization Using an Intel IPU and Disaggregated NVMe Storage at Intel Innovation